Latest Insider Transactions at Nevro Corp (NVRO)
This section provides a real-time view of insider transactions for Nevro Corp (NVRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEVRO CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEVRO CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
750
-1.21%
|
$120,750
$161.34 P/Share
|
|
Dec 10
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+2.36%
|
$48,000
$64.95 P/Share
|
|
Dec 02
2020
|
Susan E Siegel |
BUY
Grant, award, or other acquisition
|
Direct |
1,883
+50.0%
|
-
|
|
Nov 10
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
750
-2.41%
|
$127,500
$170.75 P/Share
|
|
Nov 10
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+2.36%
|
$48,000
$64.95 P/Share
|
|
Nov 01
2020
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,192
-6.84%
|
$326,608
$149.21 P/Share
|
|
Oct 22
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,817
-5.65%
|
$299,805
$165.0 P/Share
|
|
Oct 19
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-3.02%
|
$155,000
$155.0 P/Share
|
|
Oct 13
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
750
-2.21%
|
$113,250
$151.47 P/Share
|
|
Oct 13
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+2.16%
|
$48,000
$64.95 P/Share
|
|
Oct 12
2020
|
Michael F Demane Director |
SELL
Open market or private sale
|
Direct |
903
-0.19%
|
$136,353
$151.35 P/Share
|
|
Oct 09
2020
|
Michael F Demane Director |
SELL
Open market or private sale
|
Direct |
20,529
-7.97%
|
$3,079,350
$150.31 P/Share
|
|
Oct 09
2020
|
Niamh Louise Pellegrini Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-2.93%
|
$150,000
$150.0 P/Share
|
|
Sep 30
2020
|
Elizabeth H Weatherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
123
+0.73%
|
-
|
|
Sep 30
2020
|
Brad Vale Director |
BUY
Grant, award, or other acquisition
|
Direct |
113
+0.91%
|
-
|
|
Sep 30
2020
|
Frank M Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
120
+0.3%
|
-
|
|
Sep 30
2020
|
Michael F Demane Director |
BUY
Grant, award, or other acquisition
|
Direct |
199
+0.08%
|
-
|
|
Jun 08
2015
|
Johnson & Johnson > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,010,265
-32.83%
|
$47,482,455
$47.94 P/Share
|
|
Nov 12
2014
|
Johnson & Johnson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,000
+1.28%
|
$720,000
$18.0 P/Share
|
|
Nov 12
2014
|
Johnson & Johnson > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,037,005
+50.0%
|
-
|